Core Viewpoint - Conavi Medical Corp. has successfully closed an equity offering, raising approximately $12 million to support the commercialization of its Novasight Hybrid system and other corporate purposes [1][2][4]. Group 1: Offering Details - The equity offering generated gross proceeds of approximately $12 million, with subscribers purchasing 26,666,670 common shares at a price of $0.45 per share [1][3]. - The proceeds will be utilized for obtaining US FDA 510(k) clearance for the Novasight Hybrid system and initiating a targeted market release in the United States, along with working capital and general corporate purposes [2][4]. Group 2: Company Background - Conavi Medical focuses on designing, manufacturing, and marketing imaging technologies for minimally invasive cardiovascular procedures, with its Novasight Hybrid system being the first to combine intravascular ultrasound (IVUS) and optical coherence tomography (OCT) [7]. - The first-generation Novasight Hybrid system has already received 510(k) regulatory clearance in the U.S., Canada, China, and Japan [7]. Group 3: Agent and Compensation - Bloom Burton Securities Inc. acted as the sole agent for the offering, receiving a total cash commission of approximately $701,479.49 and 1,558,843 compensation options, each allowing the purchase of one common share at $0.45 until January 13, 2028 [3][6].